A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment

April 07, 2021
https://clinicaltrials.gov/ct2/show/NCT04369430
Parkinson Disease
Principal Investigator: Bisena Bulica, DO
Brain Diseases,  Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Parkinson's Disease
Completed
248-661-7257